Malignancies after renal transplantation during 33 years at a single center

Pathology and Oncology Research

Volumn 13, Issue 1, 2007, Pages 63-69

  Végso, Gyula ^a   Tóth, Mária ^b   Hídvégi, Márta ^a   Toronyi, Éva ^a   Langer, Robert M ^a   Dinya, Elek ^b   Tóth, András ^a   Perner, Ferenc ^a   Járay, Jeno ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b EGIS PHARMACEUTICALS LTD   (Hungary)

Author keywords

Immunosuppression; Kidney transplantation; Posttransplant malignancies; Tumor risk; Waiting list

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY CANCER; KIDNEY TRANSPLANTATION; LIVER CANCER; LUNG CANCER; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUTH CANCER; PROSTATE CANCER; SKIN CANCER; STOMACH CANCER; THYROID CANCER;

EID: 34249989036     PISSN: 12194956     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893443     Document Type: Article

References (20)

1. Buell JF, Gross TG, Woodle ES: Malignancy after transplantation. Transplantation 80: S254-264, 2005
2. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplant 4: 905-913, 2004
3. Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, Ekbom A, Adami HO, Granath F: Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer 89: 1221-1227, 2003
4. Montagnino G, Lorca E, Tarantino A, Bencini P, Aroldi A, Cesana B, Braga M, Lonati F, Ponticelli C: Cancer incidence in 854 kidney transplant recipients from a single institution: comparison with normal population and with patients under dialytic treatment. Clin Transpl 10: 461-469, 1996
5. Lutz J, Heemann U: Tumors after kidney transplantation. Curr Opin Urol 13: 105-109, 2003
6. Penn I: Cancers in renal transplant recipients. Adv Ren Replace Ther 7: 147-156, 2000
7. Penn I: Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 12: 147-158, 1998
8. Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW: Post-transplant de novo malignancies in renal transplant recipients: the past and present. Transpl Int 19: 607-620, 2006
9. Desoize B: Immunosuppressive agents are also carcinogens. Crit Rev Oncol Hematol 56: 1-4, 2005
10. Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K: Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80: 1233-1243, 2005
11. Opelz G, Döhler B: Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 4: 222-230, 2004
12. Taylor AL, Marcus R, Bradley JA: Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplantation. Crit Rev Oncol Hematol 56: 155-167, 2005
13. Mathew T, Kreis H, Friend P: Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transpl 18: 446-449, 2004
14. Ottó S, Kásler M: Trends in cancer mortality and morbidity in Hungarian and international statistics. Characteristics and potential outcome of public health screening programmes. (In Hungarian) Hungarian Oncology 49:99-107, 2005
15. Penn I: Transmission of cancer from organ donors. Ann Transplant 2: 7-12, 1997
16. Kinlen LJ, Eastwood JB, Kerr DN, Moorhead JF, Oliver DO, Robinson BH, de Wardener HE, Wing AJ: Cancer in patients receiving dialysis. Br Med J 280: 1401-1403, 1980
17. Fischereder M, Jauch KW: Prevalence of cancer history prior to renal transplantation. Transpl Int 18: 779-784, 2005
18. Kahan BD, Knight R, Schoenberg L, Pobielski J, Kerman RH, Mahalati K, Yakupoglu Y, Aki FT, Katz S, Van Buren CT: Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc 35: 25S-34S, 2003
19. Yakupoglu YK, Buell JF, Woodle S, Kahan BD: Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 38: 358-361, 2006
20. Taylor AL, Watson CJ, Bradley JA: Immunosuppressive agents in solid organ transplantation: Mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 56: 23-46, 2005